RT Journal Article
SR Electronic
T1 Vessel Dilator and Kaliuretic Peptide Inhibit ERK 1/2 Activation in Human Prostate Cancer Cells
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3217
OP 3222
VO 26
IS 5A
A1 YING SUN
A1 EHRENTRAUD J. EICHELBAUM
A1 HAI WANG
A1 DAVID L. VESELY
YR 2006
UL http://ar.iiarjournals.org/content/26/5A/3217.abstract
AB Background: Vessel dilator and kaliuretic peptide have anticancer effects in human prostate adenocarcinomas. Materials and Methods: Vessel dilator, kaliuretic peptide and cyclic GMP's effects on ERK 1/2 kinase were examined in human prostate adenocarcinoma cells. Results: Vessel dilator and kaliuretic peptide decreased the activation of ERK 1/2 over a concentration range of 0.01 μM to 1 μM. Vessel dilator and kaliuretic peptide (each 1 μM) inhibited the phosphorylation of ERK 1/2 kinase 96% (p<0.0001) and 70% (p<0.001), respectively. Both had significant effects within five minutes at their 0.01 μM concentrations. The inhibition of ERK 1/2 lasted for at least two hours secondary to both. Their ability to inhibit ERK 1/2 was decreased by cyclic GMP antibody and cyclic GMP itself decreased ERK 1/2 phosphorylation. Conclusion: Vessel dilator and kaliuretic peptide both inhibit ERK 1/2 kinase mediated via cyclic GMP as part of their anticancer mechanism(s) of action. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved